Drugs / 17-hydroxyprogesterone caproate
17-hydroxyprogesterone caproate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00120640 | Jul 2005 → ? | — | Yale University | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03292731 Comparator | Feb 2018 → Sep 2021 | — | Steve N. Caritis, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT01050647 Comparator | Feb 2010 → Dec 2015 | pregnancy disorder | Stanford University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04807543 Comparator | Jan 2018 → Oct 2020 | preterm premature rupture of the membranes | Ain Shams University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02913495 Comparator | Sep 2016 → Aug 2021 | — | Thomas Jefferson University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00694967 Comparator | Nov 2003 → Dec 2006 | cervix disorder | Lehigh Valley Hospital | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 17 hydroxyprogesterone caproate | “250 mg intramuscular 17-hydroxyprogesterone caproate weekly” PMID 35189093 ↗ Feb 2022 |
| Known as | 17 alpha hydroxprogesterone caproate | “Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)” NCT02913495 ↗ |
| Known as | 17-OHPC | “The study plans to determine the relationship between plasma concentrations of 17-OHPC hydroxyprogesterone caproate (17-OHPC) and the rate of preterm birth.” NCT03292731 ↗ |
| Known as | 17P | “We hypothesized that weekly intramuscular injections of 17 hydroxyprogesterone caproate(17P) will reduce the number spontaneous preterm births prior to 35 weeks gestation when...” NCT00694967 ↗1“17 alpha-hydroxyprogesterone caproate (17P)” NCT00120640 ↗ |
| Known as | hydroxyprogesterone caproate | “The study plans to determine the relationship between plasma concentrations of 17-OHPC hydroxyprogesterone caproate (17-OHPC) and the rate of preterm birth.” NCT03292731 ↗ |
| Route | Intramuscular | “intramuscular injections” NCT00120640 ↗ |